Редактирование: PRX

Periaxin [KIAA1620]

==Publications==

{{medline-entry
|title=Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents?
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/21329552
|abstract=Selective serotonin reuptake inhibitor use is associated with increased risk of suicidal ideation in adolescent humans, yet the neuropharmacological basis of this phenomenon is unknown. Consequently, we examined the behavioural and neurochemical effects of chronic paroxetine ([[PRX]]) treatment in adult and adolescent rats. Rats received [[PRX]] in their drinking water (target dose 10 mg/kg) for 22 d, during which time they were assessed for depression- and anxiety-like behaviours. Subsequent ex-vivo analyses examined serum [[PRX]] concentrations, striatal neurotransmitter content, and regional serotonin and dopamine transporter (SERT, DAT) binding density. After 11-12 d treatment, [[PRX]]-treated adolescent rats showed a significant inhibition of social interaction while adults were unaffected. After 19-20 d treatment, adolescents failed to show an antidepressant-like effect of [[PRX]] treatment on the forced swim test ([[FST]]), while [[PRX]]-treated adults showed a typical decrease in immobility and increase in swimming. Two [[PRX]]-treated adolescents died unexpectedly after the [[FST]] suggesting a compromised response to physical stress. Despite their greater apparent adverse reaction to the drug, adolescents had significantly lower plasma [[PRX]] than adults at day 22 of treatment. Chronic [[PRX]] treatment had similar effects in adults and adolescents on striatal 5-HT (unchanged relative to controls) and 5-HIAA levels (decreased), while markers of dopaminergic function (DOPAC, HVA, DA turnover) were increased in adults only. SERT density was up-regulated in the amygdala in [[PRX]]-treated adolescents only while DAT density in the nucleus accumbens was down-regulated only in [[PRX]]-treated adults. These data suggest that the immature rat brain responds differently to [[PRX]] and that this might be of use in modelling the atypical response of human adolescents to antidepressants. The age-specific [[PRX]]-induced changes in dopaminergic markers and SERT and DAT binding provide clues as to the neural mechanisms underlying adverse [[PRX]] effects in adolescent humans.
|mesh-terms=* Adolescent
* Aging
* Animals
* Antidepressive Agents
* Behavior, Animal
* Corpus Striatum
* Dopamine Plasma Membrane Transport Proteins
* Humans
* Male
* Neurotransmitter Agents
* Paroxetine
* Rats
* Rats, Wistar
* Serotonin Plasma Membrane Transport Proteins
* Serotonin Uptake Inhibitors
* Time Factors

|full-text-url=https://sci-hub.do/10.1017/S146114571100006X
}}
{{medline-entry
|title=Proteomic DIGE analysis of the mitochondria-enriched fraction from aged rat skeletal muscle.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/19834913
|abstract=Skeletal muscle aging is associated with a loss in tissue mass and contractile strength, as well as fiber type shifting and bioenergetic adaptation processes. Since mitochondria represent the primary site for energy generation via oxidative phosphorylation, we investigated potential changes in the expression pattern of the mitochondrial proteome using the highly sensitive DIGE approach. The comparative analysis of the mitochondria-enriched fraction from young adult versus aged muscle revealed an age-related change in abundance for 39 protein species. MS technology identified the majority of altered proteins as constituents of muscle mitochondria. An age-dependent increase was observed for NADH dehydrogenase, the mitochondrial inner membrane protein mitofilin, peroxiredoxin isoform [[PRX]]-III, ATPase synthase, succinate dehydrogenase, mitochondrial fission protein Fis1, succinate-coenzyme A ligase, acyl-coenzyme A dehydrogenase, porin isoform [[VDAC2]], ubiquinol-cytochrome c reductase core I protein and prohibitin. Immunoblotting, enzyme testing and confocal microscopy were used to validate proteomic findings. The DIGE-identified increase in key mitochondrial elements during aging agrees with the concept that sarcopenia is associated with a shift to a slower contractile phenotype and more pronounced aerobic-oxidative metabolism. This suggests that mitochondrial markers are reliable candidates that should be included in the future establishment of a biomarker signature of skeletal muscle aging.
|mesh-terms=* Aging
* Animals
* Electrophoresis, Gel, Two-Dimensional
* Mitochondria, Muscle
* Mitochondrial Proteins
* Muscle Fibers, Skeletal
* Muscle, Skeletal
* Proteome
* Proteomics
* Rats
* Rats, Wistar

|full-text-url=https://sci-hub.do/10.1002/pmic.200900472
}}
{{medline-entry
|title=[[PRX]]-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/19576924
|abstract=To address the development of early anxiety disorders across the lifespan, the High USV line of rats was bred based on rates of infant ultrasonic vocalization in the 40-50 kHz range of predominant frequencies (USV) to maternal separation at postnatal day (P) 10. In this study, rates of USV in High line infants (pups: Postnatal Day 11 /-1) were compared to those of randomly-bred controls in response to EPIX compound [[PRX]]-00023, a unique serotonin (5-HT) agonist, acting exclusively at the 5-HT1A receptor, or buspirone, a nonspecific 5HT1A agonist. After testing, pups were examined for sedation and other drug-related effects. The results indicated that all doses of buspirone reduced USV rates in isolation, consistent with other reports. [[PRX]]-00023 significantly reduced USV rates at the lowest doses (0.01-0.05 mg/kg). None of the [[PRX]]-00023 doses produced sedation, whereas all but the lowest dose of buspirone (0.1 mg/kg) produced sedation effects. The results suggest that this compound alleviates infantile anxiety-like behavior with great specificity in rats bred for high anxiety/depressive phenotypes by selectively targeting 5-HT1A receptors, possibly by both pre- and post-synaptic mechanisms.
|mesh-terms=* Aging
* Animals
* Anti-Anxiety Agents
* Anxiety
* Anxiety Disorders
* Anxiety, Separation
* Ataxia
* Body Temperature
* Buspirone
* Disease Models, Animal
* Dose-Response Relationship, Drug
* Eliminative Behavior, Animal
* Female
* Grooming
* Hybridization, Genetic
* Male
* Movement
* Piperazines
* Rats
* Reaction Time
* Serotonin 5-HT1 Receptor Agonists
* Sex Characteristics
* Social Isolation
* Sulfonamides
* Ultrasonics
* Vocalization, Animal

|full-text-url=https://sci-hub.do/10.1016/j.pbb.2009.06.014
}}